The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...
ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...
ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...
In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...
StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...
Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (ONC – Research Report), boosting the price target to ...
28,064 people played the daily Crossword recently. Can you solve it faster than others?28,064 people played the daily Crossword recently. Can you solve it faster than others? Warren Buffett Sends ...
Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates (ADCs) and other assets in the final few days of ...
The European Commission has approved BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy as a first-line treatment for oesophageal squamous cell carcinoma (ESCC ...
BeiGene said U.S. regulators had approved its Tevimbra to treat a form of stomach cancer. The oncology company said the Food and Drug Administration approved Tevimbra in combination with platinum ...